Bridging the gaps in the vaccine development

Avant-garde vaccine approach with secreted heat shock protein gp96-Ig

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Design of highly pure and safe vaccines in post-genomic era unfortunately includes the inherent lack of immunostimulatory properties of proteins and peptides. Vaccine adjuvants are therefore considered key components in modern vaccinology since they provide the necessary help of enhancing the immune responses. Over the past two decades, Dr. Podack's laboratory has developed an exciting and avant-garde reagent: a heat shock protein-based vaccine, chaperone gp96, that generates effective antitumor and anti-infectious immunity in vivo. State-of- the- art secreted gp96-Ig vaccine provides within one molecule strong adjuvant properties and antigen specificity for cross-priming CD8 T cells and activation of innate immunity. Gp96-peptide complexes were identified as an extremely efficient, femto-molar pathway of MHC I-mediated antigen cross-presentation, generating CD8 CTL responses detectable in the blood, spleen, liver, intestinal and reproductive tract lamina propria, and intraepithelial compartment, respectively. These studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce not only systemic but also mucosal immunity. The gp96-Ig vaccine strategy has been utilized in clinical trials for non-small cell lung cancer (NSCLC) patients and as prophylactic SIV vaccine to protect nonhuman primates from mucosal infection upon challenge with SIV, demonstrating the feasibility and benefits of this approach for both safety and efficacy.

Original languageEnglish (US)
Title of host publicationHeat Shock Proteins in the Immune System
PublisherSpringer International Publishing
Pages75-95
Number of pages21
ISBN (Electronic)9783319690421
ISBN (Print)9783319690407
DOIs
StatePublished - Apr 9 2018

Fingerprint

Heat-Shock Proteins
Vaccines
Cross-Priming
SAIDS Vaccines
Antigens
Mucosal Immunity
Peptides
T-cells
Antigen Presentation
Innate Immunity
Non-Small Cell Lung Carcinoma
Liver
Primates
Immunity
Mucous Membrane
Blood
Spleen
Chemical activation
Cells
Clinical Trials

Keywords

  • Cancer
  • gp96
  • Heat shock proteins
  • HIV
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Medicine(all)
  • Immunology and Microbiology(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Bridging the gaps in the vaccine development : Avant-garde vaccine approach with secreted heat shock protein gp96-Ig. / Strbo, Natasa.

Heat Shock Proteins in the Immune System. Springer International Publishing, 2018. p. 75-95.

Research output: Chapter in Book/Report/Conference proceedingChapter

Strbo, Natasa. / Bridging the gaps in the vaccine development : Avant-garde vaccine approach with secreted heat shock protein gp96-Ig. Heat Shock Proteins in the Immune System. Springer International Publishing, 2018. pp. 75-95
@inbook{318615ca03a3459c9bc6d158fb93045d,
title = "Bridging the gaps in the vaccine development: Avant-garde vaccine approach with secreted heat shock protein gp96-Ig",
abstract = "Design of highly pure and safe vaccines in post-genomic era unfortunately includes the inherent lack of immunostimulatory properties of proteins and peptides. Vaccine adjuvants are therefore considered key components in modern vaccinology since they provide the necessary help of enhancing the immune responses. Over the past two decades, Dr. Podack's laboratory has developed an exciting and avant-garde reagent: a heat shock protein-based vaccine, chaperone gp96, that generates effective antitumor and anti-infectious immunity in vivo. State-of- the- art secreted gp96-Ig vaccine provides within one molecule strong adjuvant properties and antigen specificity for cross-priming CD8 T cells and activation of innate immunity. Gp96-peptide complexes were identified as an extremely efficient, femto-molar pathway of MHC I-mediated antigen cross-presentation, generating CD8 CTL responses detectable in the blood, spleen, liver, intestinal and reproductive tract lamina propria, and intraepithelial compartment, respectively. These studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce not only systemic but also mucosal immunity. The gp96-Ig vaccine strategy has been utilized in clinical trials for non-small cell lung cancer (NSCLC) patients and as prophylactic SIV vaccine to protect nonhuman primates from mucosal infection upon challenge with SIV, demonstrating the feasibility and benefits of this approach for both safety and efficacy.",
keywords = "Cancer, gp96, Heat shock proteins, HIV, Immunotherapy, Vaccine",
author = "Natasa Strbo",
year = "2018",
month = "4",
day = "9",
doi = "10.1007/978-3-319-69042-1_5",
language = "English (US)",
isbn = "9783319690407",
pages = "75--95",
booktitle = "Heat Shock Proteins in the Immune System",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Bridging the gaps in the vaccine development

T2 - Avant-garde vaccine approach with secreted heat shock protein gp96-Ig

AU - Strbo, Natasa

PY - 2018/4/9

Y1 - 2018/4/9

N2 - Design of highly pure and safe vaccines in post-genomic era unfortunately includes the inherent lack of immunostimulatory properties of proteins and peptides. Vaccine adjuvants are therefore considered key components in modern vaccinology since they provide the necessary help of enhancing the immune responses. Over the past two decades, Dr. Podack's laboratory has developed an exciting and avant-garde reagent: a heat shock protein-based vaccine, chaperone gp96, that generates effective antitumor and anti-infectious immunity in vivo. State-of- the- art secreted gp96-Ig vaccine provides within one molecule strong adjuvant properties and antigen specificity for cross-priming CD8 T cells and activation of innate immunity. Gp96-peptide complexes were identified as an extremely efficient, femto-molar pathway of MHC I-mediated antigen cross-presentation, generating CD8 CTL responses detectable in the blood, spleen, liver, intestinal and reproductive tract lamina propria, and intraepithelial compartment, respectively. These studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce not only systemic but also mucosal immunity. The gp96-Ig vaccine strategy has been utilized in clinical trials for non-small cell lung cancer (NSCLC) patients and as prophylactic SIV vaccine to protect nonhuman primates from mucosal infection upon challenge with SIV, demonstrating the feasibility and benefits of this approach for both safety and efficacy.

AB - Design of highly pure and safe vaccines in post-genomic era unfortunately includes the inherent lack of immunostimulatory properties of proteins and peptides. Vaccine adjuvants are therefore considered key components in modern vaccinology since they provide the necessary help of enhancing the immune responses. Over the past two decades, Dr. Podack's laboratory has developed an exciting and avant-garde reagent: a heat shock protein-based vaccine, chaperone gp96, that generates effective antitumor and anti-infectious immunity in vivo. State-of- the- art secreted gp96-Ig vaccine provides within one molecule strong adjuvant properties and antigen specificity for cross-priming CD8 T cells and activation of innate immunity. Gp96-peptide complexes were identified as an extremely efficient, femto-molar pathway of MHC I-mediated antigen cross-presentation, generating CD8 CTL responses detectable in the blood, spleen, liver, intestinal and reproductive tract lamina propria, and intraepithelial compartment, respectively. These studies provided the first evidence that cell-based gp96-Ig-secreting vaccines may serve as a potent modality to induce not only systemic but also mucosal immunity. The gp96-Ig vaccine strategy has been utilized in clinical trials for non-small cell lung cancer (NSCLC) patients and as prophylactic SIV vaccine to protect nonhuman primates from mucosal infection upon challenge with SIV, demonstrating the feasibility and benefits of this approach for both safety and efficacy.

KW - Cancer

KW - gp96

KW - Heat shock proteins

KW - HIV

KW - Immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85053537636&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053537636&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-69042-1_5

DO - 10.1007/978-3-319-69042-1_5

M3 - Chapter

SN - 9783319690407

SP - 75

EP - 95

BT - Heat Shock Proteins in the Immune System

PB - Springer International Publishing

ER -